ANKRD11 (Ankyrin Repeat Domain 11) encodes a transcriptional regulator containing ankyrin repeat domains. It acts as a cofactor for histone acetylation and is crucial for neuronal development and function. This gene is notable for causing KBG syndrome when mutated and for its broader roles in chromatin regulation and neurodevelopment.
ANKRD11 (Ankyrin Repeat Domain 11) encodes a transcriptional co-regulator that modulates gene expression through histone acetylation. It is highly expressed in the brain and has been implicated in neurodevelopment and neurodegeneration. Mutations cause KBG syndrome, characterized by intellectual disability, dysmorphic features, and macrocephaly. [1]
ANKRD11 is a member of the ankyrin repeat-containing family of transcriptional regulators. It functions as a histone acetyltransferase coactivator, interacting with p300/CBP to enhance transcription of genes involved in neuronal development, synaptic function, and cell growth. The gene is located on chromosome 16q24.3 and encodes a protein of 2,556 amino acids. [2]
The ANKRD11 gene spans approximately 15 kb on chromosome 16q24.3 and contains 13 exons. It encodes multiple transcripts due to alternative splicing. The gene is conserved across mammals, with high expression in brain and other tissues.
ANKRD11 contains several functional domains:
The ankyrin repeat domain is the defining feature of ANKRD11, with each repeat forming a characteristic helix-turn-helix structure that mediates specific protein-protein interactions. These repeats allow ANKRD11 to interact with various transcription factors and co-regulators. [3]
ANKRD11 functions primarily as a transcriptional coactivator:
By promoting histone acetylation, ANKRD11 enables access to DNA for the transcription machinery, thereby enhancing expression of genes involved in neuronal development and synaptic plasticity. [4]
During brain development, ANKRD11 plays critical roles:
Loss of ANKRD11 function during development leads to the characteristic features of KBG syndrome, including intellectual disability and abnormal brain development. [5]
In mature neurons, ANKRD11 continues to play important roles:
ANKRD11 is particularly important for maintaining proper synaptic function, and its loss contributes to the cognitive deficits seen in KBG syndrome. [6]
Beyond the nervous system, ANKRD11 affects:
Dysregulation of these functions may contribute to the growth abnormalities seen in KBG syndrome patients. [7]
ANKRD11 shows widespread but specific expression:
In the brain, ANKRD11 expression is highest during embryonic development and early postnatal periods, coinciding with active neurogenesis and synaptogenesis. Expression is maintained in adulthood but at lower levels, suggesting ongoing roles in synaptic function. [8]
KBG syndrome is an autosomal dominant neurodevelopmental disorder caused by heterozygous ANKRD11 mutations:
Genetics:
Clinical Features:
The phenotype can vary even among individuals with the same mutation, suggesting the influence of genetic background and environmental factors. [9]
Mechanism:
ANKRD11 is implicated in autism spectrum disorder:
The synaptic dysfunction caused by ANKRD11 haploinsufficiency may disrupt neural circuit formation, contributing to autism phenotypes. [10]
ANKRD11 is one of the more common genetic causes of intellectual disability:
Seizures are a common feature of ANKRD11-related disorders:
ANKRD11 has been implicated in cancer:
The tumor suppressor function appears to be distinct from the neurodevelopmental effects. [11]
Gallagher et al. ANKRD11 and transcriptional regulation (2015). 2015. ↩︎
Sirmaci et al. ANKRD11 mutations cause KBG syndrome (2011). 2011. ↩︎
Tzeng et al. ANKRD11 and chromatin remodeling (2017). 2017. ↩︎
Yang et al. ANKRD11 and p300/CBP interaction (2021). 2021. ↩︎
Campos et al. ANKRD11 in neural development (2014). 2014. ↩︎
Liu et al. ANKRD11 in synaptic plasticity (2020). 2020. ↩︎
Mueller et al. ANKRD11 and brain development (2019). 2019. ↩︎
Benetti et al. ANKRD11 in intellectual disability (2017). 2017. ↩︎
Barsalou et al. KBG syndrome genotype-phenotype correlation (2020). 2020. ↩︎
Kelley et al. ANKRD11 in autism spectrum disorder (2020). 2020. ↩︎
Iyer et al. ANKRD11 and cancer metabolism (2018). 2018. ↩︎